
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen Inc. is positioned positively in the biotechnology sector, supported by its Enhanced Delivery Oligonucleotide platform, which aims to revolutionize the treatment of severe neuromuscular and neurologic diseases. The company's pipeline, featuring products like PGN-EDO51 and PGN-EDODM1, indicates significant potential for advancement, particularly as multi-dose data is anticipated to reveal a favorable risk/benefit profile. Currently trading at approximately $4 per share, analysts note that the stock presents meaningful upside potential, especially in light of projected valuation adjustments based on future clinical data results.
Bears say
PepGen Inc's financial outlook is negatively affected by a recent decrease in the target share price, which has been revised downwards to $8 per share due to concerns about the company's ability to execute commercially and meet performance expectations. Additionally, there is a significant risk that failure to access capital markets could lead to delays or even termination of ongoing development campaigns, adversely impacting the company's pipeline of oligonucleotide therapeutics. This combination of potential execution challenges and financial constraints creates a bleak perspective for investors regarding the future performance of PepGen's stock.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares